Connor Clark & Lunn Investment Management Ltd. Has $8.82 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 466.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 26,425 shares of the company’s stock after buying an additional 21,764 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.09% of Medpace worth $8,821,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Signaturefd LLC lifted its position in Medpace by 4.9% in the 2nd quarter. Signaturefd LLC now owns 559 shares of the company’s stock valued at $230,000 after acquiring an additional 26 shares in the last quarter. Wealth Alliance raised its stake in shares of Medpace by 2.9% in the 2nd quarter. Wealth Alliance now owns 970 shares of the company’s stock valued at $399,000 after purchasing an additional 27 shares during the period. Commonwealth Equity Services LLC lifted its holdings in shares of Medpace by 0.7% in the second quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock valued at $1,787,000 after purchasing an additional 32 shares in the last quarter. Lindenwold Advisors INC boosted its position in shares of Medpace by 1.6% during the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock worth $676,000 after buying an additional 32 shares during the period. Finally, Nations Financial Group Inc. IA ADV grew its holdings in shares of Medpace by 1.7% during the third quarter. Nations Financial Group Inc. IA ADV now owns 2,376 shares of the company’s stock worth $793,000 after buying an additional 39 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of recent research reports. Redburn Atlantic assumed coverage on Medpace in a research report on Monday, October 14th. They set a “buy” rating and a $404.00 price target for the company. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and decreased their target price for the company from $415.00 to $345.00 in a research report on Wednesday, September 25th. TD Cowen cut their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Robert W. Baird cut Medpace from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $413.00 to $349.00 in a report on Wednesday, October 23rd. Finally, William Blair reiterated an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and a consensus price target of $380.00.

Medpace Stock Up 4.8 %

MEDP opened at $341.87 on Friday. Medpace Holdings, Inc. has a 12-month low of $268.80 and a 12-month high of $459.77. The business has a 50 day moving average of $340.48 and a 200-day moving average of $373.99. The stock has a market cap of $10.63 billion, a price-to-earnings ratio of 29.94, a PEG ratio of 1.74 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The business had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. During the same quarter last year, the firm posted $2.22 EPS. The company’s quarterly revenue was up 8.3% on a year-over-year basis. As a group, analysts expect that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.